TransMedics Group, Inc. (TMDX) 은(는) 상장 기업입니다 헬스케어 섹터의 Medical - Devices 산업에서 운영. 본사 소재지는 Andover, MA, 미국. 현재 CEO는 Waleed H. Hassanein.
TMDX 을(를) 보유 IPO 날짜 2019-05-02, 728 명의 정규직 직원, 에 상장 NASDAQ Global Market, 시가총액 $3.97B.
TransMedics Group, Inc. is a commercial-stage medical technology company headquartered in Andover, Massachusetts, focused on transforming organ transplant therapy for end-stage organ failure patients globally. The company develops and commercializes the Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring platform that uses proprietary technology to maintain near-physiologic conditions for donor organs outside the human body. Its product portfolio includes OCS LUNG for lung preservation, OCS Heart for cardiac preservation, and OCS Liver for hepatic preservation, each designed to improve transplant outcomes and expand the pool of viable organs. Founded in 1998, TransMedics addresses critical challenges in organ transplantation through innovative ex vivo organ preservation technology.